Top Biotechnology Startups in 2026

H1 was built by scientists for scientists. We empower stakeholders at healthcare and life science companies to make smarter scientific decisions by providing access to critical data through an intuitive interface. Working with some of the largest and most influential global life science organizations, H1 provides insight into thought leaders, scholarly content, academics, and healthcare professionals with much more on the way.

TrialSpark is transforming the way new medical treatments are brought to market. We’re a technology company that runs end-to-end clinical trials through a network of our own TrialSpark-operated trial sites, making the entire lifecycle of clinical trials more efficient, accessible, and patient-centric. We're growing quickly and would love to have you join us!

Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments.

Synonym is a financing and development platform for essential biomanufacturing infrastructure - we’re building production capacity for synthetic biology companies and creating a new asset class for investors. We provide synbio companies with flexible capacity for microbial fermentation.  We build new biomanufacturing facilities, offering synbio companies access to dedicated, scalable capacity for minimal upfront capital investment. We accelerate project timelines and minimize internal complexity by handling facility development activities, from site selection through commissioning. We provide capital markets partners with curated access to biomanufacturing infrastructure investments, an emerging asset class and we manage these investments on behalf of investors, with an emphasis on risk management and maximizing returns.

Ginkgo Bioworks engineers organisms to address fundamental challenges the world is facing today. We aren't trying to study biology, we are trying to build it - constructing, editing, and redesigning the living world. Our bioengineers make use of an in-house pipeline of technologies to design and build new organisms. First biotech in YCombinator: techcrunch.com/2014/08/19/sam-altman-on-his-inaugural-batch-of-companies-as-y…

Q Bio is revolutionizing primary care with the first clinical digital twin platform, powered by breakthrough whole-body scanning technology, that highlights the most important changes in a person’s physiology for sharing with physicians and specialists anywhere in the world. The company was founded in 2015 and is headquartered in San Carlos, California. Q Bio was founded by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. We are fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant.

We push the boundaries of molecular diagnostics through quantitative technologies. BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending QCT molecular counter platform is the only technology platform that can accurately count the DNA molecules to the single-count level.

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. If you crave challenges, understudied problems, and the chance to see your work impact the millions of lives touched by cancer, there’s no better place to be. We are committed to our core values of empathy, integrity, and trust enable us to push through challenges, learn from mistakes, and support one another to reach our fullest potential. By applying advanced ML techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238M from investors such as RA Capital, Polaris Partners, Perceptive Advisors, a16z, funds/accounts advised by T. Rowe Price Associates, Inc., GV (fka Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, & Verily Life Sciences.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive karius® test that helps clinicians make rapid treatment decisions. our laboratory is clia-certified and cap-accredited to perform high-complexity clinical laboratory testing. we provide unique genomic insights by detecting microbial cell-free dna (mcfdna) circulating in the bloodstream from pathogens causing an acute infection. proprietary technology efficiently extracts mcfdna directly from blood and depletes the strong human background signal and environmental contaminants. advanced machine learning algorithms allow analysis of complex genomic data in real-time. proprietary reference genome databases are constantly refined as more data becomes available.